FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant…
Tag: 2021
Obseva Announces Appointment of Stephanie Brown to its Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – ObsEva…
ObsEva Announces Third Quarter 2021 Financial Results and Business Update
-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis:…
Q3 Report 2021
ObsEva Announces Management Change
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 29, 2021…
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
-Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster…
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot…
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-…
ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30, 2021…
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of…